{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Lantheus Holdings, Inc.
Is Lantheus Holdings, Inc. overvalued or undervalued?
As of October 17, 2025, Lantheus Holdings, Inc. is considered undervalued with a P/E ratio of 15 and an EV to EBITDA of 10.33, despite a recent year-to-date return of -37.85%, suggesting potential for recovery compared to its peers like QIAGEN NV, which has a P/E of 24.20.
Lantheus Holdings, Inc. Experiences Revision in Its Stock Evaluation Amid Market Volatility
Lantheus Holdings, Inc. has recently adjusted its valuation, with its current price at $55.60. The company has shown significant volatility over the past year, with a notable 52-week range. Key financial metrics indicate strong operational efficiency and profitability, positioning Lantheus favorably compared to its industry peers.
Is Lantheus Holdings, Inc. overvalued or undervalued?
As of October 17, 2025, Lantheus Holdings, Inc. is considered undervalued with a P/E ratio of 15 compared to the peer average of 24.20, strong performance metrics like a 56.47% ROCE, and recent stock outperformance against the S&P 500, indicating an attractive investment opportunity.
Is Lantheus Holdings, Inc. overvalued or undervalued?
As of October 17, 2025, Lantheus Holdings, Inc. has shifted from a fair to an attractive valuation grade, indicating it is undervalued with a P/E ratio of 15 and strong long-term performance, despite a recent year-to-date return of -37.85%.
Is Lantheus Holdings, Inc. technically bullish or bearish?
As of August 6, 2025, Lantheus Holdings, Inc. is in a bearish trend, indicated by negative MACD signals and underperformance with a year-to-date return of -42.37% compared to the S&P 500's 12.22%.
Is Lantheus Holdings, Inc. overvalued or undervalued?
As of July 7, 2025, Lantheus Holdings, Inc. is considered undervalued with a favorable P/E ratio of 15 and strong ROCE of 56.47%, despite a challenging YTD return of -42.37%, indicating a positive long-term growth outlook.
Is Lantheus Holdings, Inc. overvalued or undervalued?
As of August 30, 2024, Lantheus Holdings, Inc. is considered undervalued with a favorable P/E ratio of 15, strong profitability metrics (ROCE of 56.47% and ROE of 31.84%), competitive valuation ratios (EV/EBITDA of 10.33 and EV/Sales of 3.43), and positive stock performance, having outpaced the S&P 500 recently.
Is Lantheus Holdings, Inc. technically bullish or bearish?
As of June 9, 2025, Lantheus Holdings, Inc. shows a mildly bearish trend due to mixed signals from MACD, KST, and moving averages, indicating a cautious outlook.
Who are in the management team of Lantheus Holdings, Inc.?
As of March 2022, the management team of Lantheus Holdings, Inc. includes Non-Executive Independent Chairman Brian Markison, President and CEO Mary Heino, and Independent Directors Gerard Ber, James Clemmer, Samuel Leno, and Heinz Maeusli, who oversee the company's strategic direction and operations.
What does Lantheus Holdings, Inc. do?
Lantheus Holdings, Inc. develops and commercializes diagnostic medical imaging agents in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $373 million and a net profit of $73 million, with a market cap of approximately $5.39 billion.
How big is Lantheus Holdings, Inc.?
As of Jun 18, Lantheus Holdings, Inc. has a market capitalization of $5.39 billion, with net sales of $1.54 billion and a net profit of $254.31 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
